SynthesisBritish journal of clinical pharmacology2016
Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis.
Synthesis in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Periconceptional biomarkers for maternal obesity: a systematic review.Reviews in endocrine & metabolic disorders · 2023Pooled it
- Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.British journal of clinical pharmacology · 2017 · on this mapPooled it
- Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- Does green tea extract enhance the anti-inflammatory effects of exercise on fat loss?British journal of clinical pharmacology · 2020Trial
- Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.Heliyon · 2024Article
- Article
- Athrixia phylicoides tea infusion (bushman tea) improves adipokine balance, glucose homeostasis and lipid parameters in a diet-induced metabolic syndrome rat model.BMC complementary medicine and therapies · 2021Article
- Treatment of Obesity in Mitigating Metabolic Risk.Circulation research · 2020Review
- The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives.European cardiology · 2019Review
- Cancer and comorbidity: The role of leptin in breast cancer and associated pathologies.World journal of clinical cases · 2018Review
- Cardiometabolic Effects of Anti-obesity Pharmacotherapy.Current atherosclerosis reports · 2018Review
- Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.The Journal of clinical investigation · 2017Review
- Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients.Therapeutics and clinical risk management · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo conduct a systematic review and meta-analysis of relevant randomized clinical trials (RCTs) to ascertain the effect size of orlistat in modulating plasma levels of adipokines, ghrelin and C-reactive protein (CRP).
methodsMedline, SCOPUS, Web of Science and Google Scholar databases were searched. A random-effects model and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using I(2) index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of duration of treatment, percentage change in body mass index (BMI) and baseline BMI values as potential confounders of the estimated effect size.
resultsMeta-analysis suggested a significant increase in plasma levels of adiponectin [weighted mean difference (WMD): 19.18%, 95% confidence interval (CI): 5.80, 32.57, p = 0.005] and significant reductions in plasma levels of leptin (WMD: -13.24%, 95% CI: -20.69, -5.78, p = 0.001) and CRP (WMD: -11.52%, 95% CI: -16.55, -6.49, p < 0.001) following treatment with orlistat. In meta-regression, changes in plasma concentrations of adiponectin, leptin and CRP were associated with duration of treatment, but not with either change in BMI or baseline BMI values.
conclusionOrlistat is effective in increasing plasma concentrations of adiponectin and decreasing those of leptin and CRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.